Skip to main content
S 474 116th Congress Senate Health Civil actions and liability Corporate finance and management Government information and archives Inflation and prices Marketing and advertising Prescription drugs Research and development

Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019

Introduced: February 13, 2019 Introduced by: Wyden, Ron Democratic · Oregon See on congress.gov
Sign in to write a letter Sign in to watch
This bill died when the 116th Congress ended
It never became law before the 116th Congress (2019–2020) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Feb 13, 2019
Read twice and referred to the Committee on Finance.
Feb 13, 2019
Introduced in Senate
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019

This bill requires manufacturers of drugs with specified percentage increases in their wholesale costs to submit to the Centers for Medicare & Medicaid Services (CMS) written justification for certain increases in drug prices. The CMS shall publish each submission, together with an easily understandable summary, on its website. Certain proprietary information may be excluded from publication, as specified by the bill.

A manufacturer that does not comply with the bill's requirements shall be subject to civil monetary penalties.

What's happening now February 13, 2019

Read twice and referred to the Committee on Finance.

 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
 Cosponsors 7
All 7 Democratic 7
D
Peters, Gary C.
Michigan · Sep 25, 2019
 D
Smith, Tina
Minnesota · Jul 10, 2019
 D
Cortez Masto, Catherine
Nevada · Apr 30, 2019
 D
Gillibrand, Kirsten E.
New York · Mar 28, 2019
 D
Coons, Christopher A.
Delaware · Feb 13, 2019
 D
Duckworth, Tammy
Illinois · Feb 13, 2019
 D
Klobuchar, Amy
Minnesota · Feb 13, 2019
Cite this page click to expand
APA
U.S. Congress. (2026). S. 474: Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019. 116th Congress. Open America. https://openamerica.io/bill/116-S-474/
MLA
"S. 474: Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019." 116th Congress, 2026, Open America, https://openamerica.io/bill/116-S-474/.
Bluebook (legal)
S. 474, 116th Cong. (2026), https://openamerica.io/bill/116-S-474/.
Markdown link
[S. 474: Stopping the Pharmaceutical Industry from Keeping drugs Expensive (SPIKE) Act of 2019](https://openamerica.io/bill/116-S-474/)
Report a problem